The National Institutes Of Health's National Institute Of Allergy And Infectious Diseases Announced Topline Results From Preliminary Analysis Of PALM 007 Trial Of Tecovirimat For Monkeypox Virus. The Study Did Not Meet Its Primary Endpoint Of A Statistically Significant Improvement In Time To Lesion Resolution Within 28 Days Post-randomization For Patients In Congo Versus Placebo
Portfolio Pulse from Benzinga Newsdesk
The National Institutes of Health's National Institute of Allergy and Infectious Diseases announced that the PALM 007 trial of Tecovirimat for Monkeypox virus did not meet its primary endpoint. The study showed no statistically significant improvement in time to lesion resolution within 28 days post-randomization for patients in Congo versus placebo.
August 15, 2024 | 11:39 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
The PALM 007 trial of Tecovirimat, a product associated with SIGA, did not meet its primary endpoint, showing no significant improvement in lesion resolution time for Monkeypox patients.
The failure to meet the primary endpoint in the PALM 007 trial is a significant setback for Tecovirimat, a product associated with SIGA. This could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100